Latest Quote @ Fri Dec 12 04:39:13 (15 min delayed)
Last Day's Data
Maxygen, Inc., a biotechnology company, focuses on using protein optimization and modification technologies to create and develop products for human therapeutics applications. It engages in the development of novel products for the treatment and prevention of a range of diseases, such as cancer, multiple sclerosis, HIV, and hepatitis. The company's product pipeline comprises MAXY-ALPHA, an optimized interferon alpha to treat hepatitis C; MAXY-GCSF, an improved colony stimulating factor (G-CSF) to treat neutropenia; MAXY-FACTOR VII, an improved factor VII for uncontrolled bleeding indications; and MAXY-GAMMA, an optimized interferon gamma to treat idiopathic pulmonary fibrosis and other severe diseases. Maxygen also has interest in Codexis, Inc., which provides biocatalysis and fermentation processes and products to the life science and fine chemical industries. The company has strategic alliances with F. Hoffmann-La Roche, Ltd. and InterMune, Inc. Maxygen was co-founded by Russell J. Howard and Isaac Stein. The company was incorporated in 1996 and is headquartered in Redwood City, California.